Follow
Vignesh Narayan Hariharan
Vignesh Narayan Hariharan
Verified email at umassmed.edu
Title
Cited by
Cited by
Year
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
A Biscans, J Caiazzi, N McHugh, V Hariharan, M Muhuri, A Khvorova
Molecular Therapy 29 (4), 1382-1394, 2021
442021
Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1
SM Davis, VN Hariharan, A Lo, AA Turanov, D Echeverria, J Sousa, ...
Molecular Therapy-Nucleic Acids 29, 135-149, 2022
182022
Cyclic di‐GMP sensing histidine kinase PdtaS controls mycobacterial adaptation to carbon sources
VN Hariharan, R Yadav, C Thakur, A Singh, R Gopinathan, DP Singh, ...
The FASEB Journal 35 (4), e21475, 2021
17*2021
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ...
Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023
132023
Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease
D O'Reilly, J Belgrad, C Ferguson, A Summers, E Sapp, C McHugh, ...
Molecular Therapy 31 (6), 1661-1674, 2023
112023
Finding hidden females in a crowd: Mate recognition in fig wasps
A Krishnan, KA Joshi, A Abraham, S Ayyub, M Lahiry, R Mukherjee, ...
Acta oecologica 57, 80-87, 2014
102014
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Q Tang, HH Fakih, M Zain UI Abideen, SR Hildebrand, K Afshari, ...
Nature Communications 14 (1), 7099, 2023
92023
Two-Component Signalling Systems of M. tuberculosis: Regulators of Pathogenicity and More
R Agrawal, VH Narayan, DK Saini
Dynamic Models of Infectious Diseases: Volume 2: Non Vector-Borne Diseases …, 2013
52013
Extended Nucleic Acid (exNA): A Novel, Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in vivo.
K Yamada, VN Hariharan, J Caiazzi, R Miller, C Furguson, E Sapp, ...
bioRxiv, 2023
32023
Dendritic amphiphilic siRNA: Selective albumin binding, in vivo efficacy, and low toxicity
HH Fakih, Q Tang, A Summers, M Shin, JE Buchwald, R Gagnon, ...
Molecular Therapy-Nucleic Acids 34, 2023
22023
Extended Nucleic Acid (exNA): A Novel, Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in vivo
VN Hariharan, J Caiazzi, R Miller, C Ferguson, E Sapp, H Fakih, Q Tang, ...
Research Square, 2023
12023
OLIGONUCLEOTIDES FOR SARS-CoV-2 MODULATION
A Khvorova, J Watts, Z Kennedy, A Biscans, BM da Cruz Godinho, ...
US Patent App. 17/333,839, 2023
12023
Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
A Khvorova, VN Hariharan, S Davis, A Biscans, A Karumanchi
US Patent App. 18/321,971, 2024
2024
A combinatorial approach for achieving CNS-selective RNAi
CM Ferguson, BMDC Godinho, D Echeverria, M Hassler, L Vangjeli, ...
Nucleic Acids Research, gkae100, 2024
2024
Exon 53 skipping of the human dystrophin transcript with different chemically modified AONs in a mouse model for Duchenne muscular dystrophy
S Engelbeen, D O'Reilly, D Van De Vijver, I Verhaart, M van Putten, ...
EUROPEAN JOURNAL OF HUMAN GENETICS 32, 515-516, 2024
2024
Optimized sirna scaffolds
A Khvorova, D O'reilly, VN Hariharan, C Lochmann, D Cooper
US Patent App. 18/197,948, 2023
2023
Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for …
S Engelbeen, D O'Reilly, D Van De Vijver, I Verhaart, M van Putten, ...
nucleic acid therapeutics 33 (6), 348-360, 2023
2023
Oligonucleotides for mecp2 modulation
A Khvorova, VN Hariharan
US Patent App. 18/094,695, 2023
2023
Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
A Khvorova, VN Hariharan, S Davis, A Biscans, A Karumanchi
US Patent 11,702,659, 2023
2023
Biochemical and Functional Characterization of the Mycobacterial PdtaS-PdtaR Two Component System
VN Hariharan
2021
The system can't perform the operation now. Try again later.
Articles 1–20